Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI

Platelets

Volumn 25, Issue 4, 2014, Pages 292-299

  Zhang, Hong Zhe ^c   Kim, Moo Hyun ^a,b   Jeong, Young Hoon ^d  

^a Dong A University   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d Gyeongsang National University   (South Korea)

Author keywords

Clopidogrel; LTA; MEA; VerifyNow

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ASIAN; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HUMAN; ISCHEMIA; KOREAN (PEOPLE); LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE FUNCTION ANALYZER; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTOR; SOUTH KOREA; THROMBOCYTE; THROMBOCYTE ACTIVATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROGNOSIS; REPUBLIC OF KOREA; RISK FACTORS; ROC CURVE; TICLOPIDINE;

EID: 84899979536     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.815341     Document Type: Article

References (26)

1. Steinhubl SR, Berger PB, Mann JT, Fry ET, Delago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420
2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) investigators. Lancet 2001;358:527-533
3. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-Treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56: 919-933
4. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834
5. Harrison P, Frelinger III AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120: 323-336
6. van Werkum JW, van Der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-To-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006;4:2516-2518
7. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-788
8. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van Der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762
9. Patti G, Nusca A, Manqiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDAPRO (Antiplatelet therapy for reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;30:1128-1133
10. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009;119:237-242
11. Patti G, Barczj G, Orlic D, Manqiacapra F, Colonna G, Pasceri V, Barbato E, Merkely B, Edes I, Ostojic M, et al. Outcome comparison of 600- And 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for STsegment elevation myocardial infarction: Results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 2011;58:1592-1599
12. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159
13. Kim IS, Choi BR, Jeong YH, Kwak CH, Kim S. The CYP2C19. 2 and CYP2C19. 3 polymorphisms are associated with high posttreatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009;7:897-899
14. Manqiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010;3:318-323
15. Dasqupta A, Mukherjee D. Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. Vasc Health Risk Manag 2009;5:275-286
16. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716
17. Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, Hong MK, Seo MK, Youn TJ, Chae IH, et al. Comparison of 2 point of care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J. 2011; 161:383-390
18. Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J cardiol 2009;104:285-290
19. Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, Tantry US. Platelet reactivity to adenosine diphosphate and long term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets 2008;19:595-604
20. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. High ontreatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010;104:279-286
21. Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010;104:287-292
22. Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, et al. Different prognostic significance of high on-Treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 2012;5: 259-267
23. HochholzerW, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Buttner HJ, Neumann FJ. Impact of cytochrome P450 2C19 lossof-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427-2434
24. Zhang HZ, Yu LH, Kim MH. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: A comparison between citrate and hirudin. Platelets 2013;24:339-347
25. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009;131:834-842
26. von Beackerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schomig A, Kastrati A. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. Blood Coaqul Fibrinolysis 2010;21:46-52